Adherium reported remote patient monitoring subscription accrual revenue of A$539,000, up 12.5% on the prior quarter and the fifth consecutive quarter of record revenue in that category. Customer cash receipts were A$544,000, up 33% quarter on quarter, including a A$257,917Cash Receiptfrom the AstraZeneca Arrival …
Atomo reportedRevenueof A$1.63 million for the quarter ended 30 September 2026, which the company said was growth of 140% over the comparable quarter in 2026. FebriDx orders were A$680,000 for the quarter, up 314% year on year. Cash receipts were A$2.51 million, including A$2.40 …
Cynata said it raised approximately A$912,962 before costs from its fully underwritten pro-rata renounceable entitlement offer, which followed an announcement dated 30 October 2026. The underwriter, Caravel Securities, also advised that firm commitments had been received for a placement of approximately 55 million new …
Epsilon reported quarterly receipts of A$3.9 million for the September 2026 quarter, up 34% year on year. Year-to-date revenue reached A$11.5 million, which the company said is tracking at A$16 million annualised and up 80%. Epsilon Pharmacy, established about 12 months earlier, is now …
Patrys said the first participants were dosed in its RLS-2202 Phase 1a trial at CMAX, following Human Research Ethics Committee approval. All four Cohort 1 participants completed dosing, follow-up and planned clinical assessments. After quarter end, the Safety Review Committee found the cohort had …
Telix develops and sells products that use radioactive isotopes to image and treat cancer. Its commercial revenue is dominated by Precision Medicine, which includes the PSMA-PET imaging kits Illuccix and Gozellix, used to detect prostate cancer. A second stream, TelixManufacturingSolutions (TMS), includes radiopharmacy and …
The SAPPHIRE study — formally identified as ALA-101-001 and registered under clinical trial identifier NCT07518329 — is an open-label, multi-centre, dose-escalation and expansion trial evaluating ALA-101 in patients with relapsed or refractory CD19-positive non-Hodgkin lymphoma and leukaemia. The first patient received ALA-101 at The …
The four new Bedside Hub TV customers represent healthcare organisations operating across academic, regional and specialist settings in the United States, providing geographic and institutional diversity to what is a growing installed base for the company's Epic MyChart-integrated hardware offering. Those four organisations collectively …
The deal covers four specific genotypes — MXC-THC-10/3, MXC-THC-81/5, MXC-THC-40/3 and MXC-THC-40/2 — that were developed within the Argent group but which management now classifies as non-core assets. Under the licence, TPI receives the right to cultivate, propagate, process, extract, manufacture, market, distribute, sell,Importand …
The most commercially significant change was the integration of ColoSTAT ordering into MedicalDirector, one of the most widely used general practice software systems in Australia. General practitioners using the platform can now order the test directly from their clinical workflow without leaving their practice …